🍸 33 1 86 56 03 16

Journal List Biomed Res Int PMC5745683 Biomed Res Int. 2017; 2017 3512784. Rosalie Cabry-Goubet, 1 , 2 Florence Scheffler, 1 , 2 Naima Belhadri-Mansouri, 1 Stephanie Belloc, 3 Emmanuelle Lourdel, 1 Aviva Devaux, 1 , 2 Hickmat Chahine, 4 Jacques De Mouzon, 4 Henri Copin, 1 and Moncef Benkhalifa 1 , 2 AbstractObjective To evaluate the IUI success factors relative to controlled ovarian stimulation COS and infertility type, this retrospective cohort study included 1251 couples undergoing homologous IUI. Results We achieved 13% clinical pregnancies and 11% live births. COS and infertility type do not have significant effect on IUI clinical outcomes with unstable intervention of various couples' parameters, including the female age, the IUI attempt rank, and the sperm quality. Conclusion Further, the COS used seemed a weak predictor for IUI success; therefore, the indications need more discussion, especially in unexplained infertility cases involving various factors. Indeed, the fourth IUI attempt, the female age over 40 years, and the total motile sperm count 1 × 106. The exclusion criteria were TMS ≤ 1 × 106; sperm donation; seropositivity for human immunodeficiency virus HIV for any couple member; inseminations performed in a natural cycle or with clomiphene citrate CC. IUI ProtocolAll couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin α; rFSH; Gonal-F, Merck Serono, France, or follitropin β; Puregon, MSD, France, urinary FSH urofollitropin, Fostimon, France, or hMG menotropin, Menopur, France at a starting dose of 75 IU/day from the second day of the response and endometrial thickness were monitored by transvaginal ultrasonography starting on day 6 of stimulation and then on alternate days; the gonadotropin dose was adjusted according to the ovarian response and the patient's characteristics. When at least one mature follicle reached a diameter >17 mm and E2 level > 150 pmol/mL, the recombinant human chorionic gonadotropin hCG, Ovitrelle, Merck Serono, France was administered, and endometrial thickness was single IUI was performed 36 h after hCG injection using a soft catheter classic Frydman catheter; Laboratoire CCD, Paris, France or a hard catheter SET TDT, International Laboratory CDD. The semen samples used for insemination were processed within 1 hour of ejaculation by density gradient centrifugation, followed by washing with a culture medium after determining the TMS and semen analysis according to the WHO criteria [26]. Outcome VariableThe main clinical outcome measures were clinical pregnancy and live-birth rates per cycle. Clinical pregnancy was defined as the evidence of pregnancy by ultrasound examination of the gestational sac at weeks 5– Statistical AnalysisThe stimulation protocols were divided into 4 categories according to the gonadotropin used for COS rFSH/Gonal-F, rFSH/Puregon, uFSH/Fostimon, and hMG/ type was considered in seven categories cervical factor, dysovulation, endometriosis, tubal factor, male factor, and unexplained infertility. After statistical analysis of the results, it was necessary to determine the parameter cut-offs to give infertile couples more chances through IUI before carrying out other ART techniquesGroups were compared for all main couples' characteristics and cycle outcomes. Data are presented as mean ± standard deviation SD or percentage of the total. Data were analysed with Student's t-test for means comparisons or with the chi-squared test for comparison of percentages using Statistical Package, version SAS; Institute Inc., Cary, NC, USA; p 15 Sperm motility ≥40 % versus ≤39 TMS ≥5 × 106 versus <5 s power calculation showed a power of 80% to demonstrate a difference across the COS groups in delivery rates of 10% between groups 1 and 4 and 2 and 4, of 11% between groups 3 and 4, of 8% between groups 2 and 3, of 8% between groups 2 and 4, of 7% between groups 1 and 2, 6% between recombinant FSH and urinary products, and of 9% between FSH and HMG4. DiscussionAs a first step in ART, IUI keeps a central place in the management of infertile couples for its simplicity, but it still offers weak effectiveness. Indeed, IUI success is still a subject of controversy, with a clinical pregnancy rate between 8% and 25% [16, 18, 27–31]. Furthermore, based on a recent prospective study in seven French ART centres, the overall live-birth rate was 11% per cycle, varying from 8% to 18% between centres [9]. Similarly, we attained 13% for clinical pregnancy and 11% for live-birth for the 1251 couples who underwent homologous IUI with gonadotropins for COS Table 1.Indeed, gonadotropin use had proved its superiority to improve clinical outcomes of IUI compared to other COS protocols, such as CC and letrozole [32–38]. Erdem et al. [36] showed that, for IUI success, rFSH Gonal-F was more effective than using CC to reach 28% for clinical pregnancy and 24% of live-birth. Nevertheless, it is still not clear which of the currently available medications is preferable for COS [15, 23, 39–43]. However, several studies compared different types of gonadotropin efficiency rFSH, uFSH, or hMG [15, 25, 44–47]. Indeed, in the first part of this work, we compared four gonadotropins for COS in IUI rFSH/Gonal-F; rFSH/Puregon; uFSH/Fostimon and hMG/Menopur while rFSH was the most used in 72% of couples Table 1.This preference was noticed in other studies [9, 15, 25, 36] without finding any significant improvement on clinical outcomes. Indeed, as demonstrated in our study, there was no significant difference between different protocols used for COS rFSH/Gonal-F; rFSH/Puregon; uFSH/Fostimon; and hMG/Menopur; Table 2, although, in contrast, some authors pointed to the greater potency of rFSH [22, 48]. However, other studies have reported higher pregnancy rates for hMG [33, 49–53]. Even if our study had 80% power to demonstrate differences in PR of 6% to 11% between 2 groups, according to their size, it is clear that the differences we observed were very low, in favour of a low impact of the 4 used COS regimen on the results. This was less clear for infertility origin because of the very low numbers of some groups. However, the results of the multivariate logistic model confirmed the results observed at the first step analysis, reinforcing their valueGenerally, rFSH is commonly used to minimize the possibility of developing ovarian cysts associated with LH contamination and to improve the probability of a more consistent, effective, and efficient ovarian response [22, 48].Although there was no significant difference between the efficiency of gonadotropins for COS, other COS protocol factors could be involved to improve the clinical outcomes, especially regarding the starting dose and the total doses of treatment as proved by several studies [15, 23–25, 54].To explain the absence of a significant difference between the four COS groups, we analysed other factors relative to COS protocol female age, IUI attempt rank, and sperm quality. As expected, our studied population showed its heterogeneity involving multiple factors, which was the reason not to have a real consensus about the efficiency of COS, and this made it harder to really evaluate its impact. The sperm motility significantly affected the live-birth in rFSH groups Table 3. Furthermore, the IUI attempt rank had a significant negative correlation with clinical outcomes with unequal values between groups Table 3. Indeed, it is not legitimate to consider the COS as a strong predictive factor of clinical outcomes in IUI, while other factors could not all be controlledInfertility type has been discussed throughout several studies as a nonnegligible indicator of IUI clinical outcomes [15, 30, 38, 50, 55–59], while the latest National Institute for Health and Care Excellence NICE guideline on fertility [59] recommends that IUI should not be routinely offered to people with unexplained infertility, mild endometriosis, or mild male factor infertility who are having regular unprotected sexual this reason, in the second part of this study, we were more focused on evaluating the infertility type effect on IUI success. As a result, there was no significant difference between clinical outcomes of the different groups based on the infertility type Table 4. Although unexplained infertility was most couples' indication for IUI 36% Table 1, as noticed in the recent report of Monraisin et al. [9] with a value of 39%, the lack of significant difference in clinical outcomes with other IUI indications was not unexpected, while its aetiology kept the multifactorial profile [57] shared with other infertilities. Our results are confirmed by the recent study of [38]. However, some teams report the best pregnancy rates in cervical indications [30, 55] and in anovulation infertilities [15, 50, 56]. Indeed, the pregnancy rate per cycle for patients with anovulation due to PCOS was 13%, which was probably corrected by Controlled Ovarian Hyperstimulation COH [15]. On the other hand, endometriosis was considered a bad prognostic factor for IUI success with lower pregnancy between 6% and 9% than other IUI indications [20, 50, 60]. Indeed, endometriosis, which is among the most difficult disorders to treat [21], decreased the IUI success rate for mild compared to severe cases 6% of success rate. This fact can argue the limitation of IUI to a maximum of two to three cycles [15, 19, 50, 60, 61]. This fact could explain our weak population size in the endometriosis group with just 35 couples, while the majority of couples were directed to undergo predictors of success have been widely studied on the COS effect and the infertility type effect. The most discussed effect was the age of the women, with a large debate on its impact on IUI success. Age has been accepted by many authors as a major predictive factor for pregnancy after IUI [29, 30, 60].The female age was a predictive variable for the live-birth rate but not for clinical pregnancy due to the increased miscarriage rate with age dependence, as can be observed in predictive unadjusted models [9, 57, 62]. The female age became a significant variable predictive for clinical pregnancy and live-birth rate with an adjusted model designed by Van Voorhis et al. [63] and, subsequently, Hansen et al. [57].In contrast with the aforementioned authors, our results did not show a significant correlation between the women's age and the clinical pregnancy rate Table 1, which was confirmed by several studies [11, 15, 16, 28, 64, 65]. This is due both to the intervention of other factors used in patients' selection including ovarian reserve and to the low numbers of women aged 40 or the female age impacted the success of IUI. A recent study by Bakas et al. [66] demonstrated a significant negative correlation between the age of the women and the clinical outcome of IUI r = − Indeed, with the female age cut-off of 40 years, clinical pregnancy was significantly affected Table 6 as shown throughout several studies, while the pregnancy rate decreased from 13–38% to 4–12% when the women were older than 40 years [30, 60, 67].The female age impact on IUI success could be masked in our study, because only were over 35 years and over 40 years. There may be a too low power to show a significant impact of age 40 and more in the multilogistic model, even if OR for this age category was very low Moreover, a multilogistic model including age as a continuous variable showed a significant negative impact on the delivery chance. On the other hand, age may also be linked to other factors, especially the IUI attempt rank. It is logical that, with more IUI attempts, the age advances. For this reason, Aydin et al. [68] could find no significant effect of female age on the clinical pregnancy rate in the first IUI cycle. Indeed, the rank attempt is determinant for IUI success. In our study, pregnancy rates and live births decreased significantly with the rank of insemination p = and p < resp. from rank 4 for both parameters p = see Table 6. Hendin et al. [67] and Merviel et al. [30] obtained 97% and 80%, respectively, of clinical pregnancies in their first three attempts. Plosker et al. [69] advocated a passage in IVF after three failed cycles of IUI. However, Soria et al. [15] demonstrated that from the fourth IUI cycle clinical pregnancy is negatively affected, which confirms our Blasco et al. [62] proved that the number of previous IUI cycles of the patient did not show a positive association with the cycle outcome in any of the developing steps of the models. In our study, IUI attempt rank did not have a clear correlation with clinical outcomes in different COS groups, but it did show a negative correlation with live-birth rates for patients with PCOS, unexplained infertility and male factor Tables 3 and 5. This could be explained by the evidence of severity of infertility type throughout time with an accumulation of IUI attempt failures, while IUI as a simple technique is less efficient than other ART techniques in achieving a clinical pregnancy. Particularly for infertile couples with male factor, the sperm quality becomes the determinant for IUI success [11, 70, 71], which was shown in our findings with a positive correlation of sperm concentration Table 5. It would be difficult to determine a universal threshold for sperm concentration, and each centre should define a threshold for its population and laboratory [72]. Nevertheless, Belaisch-Allart et al. [73] and Sakhel et al. [74] determined a sperm concentration cut-off at 10 × 106/mL and 5 × 106/mL, respectively. Indeed, the impact of semen quality was weak in our study, except for concentrations <5 × 106/mL, which remains nonsignificant due to small numbers of patients 8% of included population Table 6Sperm motility also appeared as a key factor in the study of Merviel et al. [30], where the pregnancy rate declined from 41% to 19% when the sperm motility was less than 70%. In our multivariable analysis with a sperm motility cut-off at 40%, we did not find any significant correlation with IUI clinical outcomes even with a large population size. This observation is reported also by Stone et al. [75].However, the TMS cut-off at 1 × 106, which was present in 21% of the included infertile patients, was a significant predictor of IUI clinical pregnancy Table 6. This finding was confirmed by two studies [9, 10] while others determined a higher threshold of TMS at 2 × 106 [68]; 3 × 106 [62, 76]; 5 × 106 [11, 77]; 10 × 106 [63, 78]. Indeed, the IUI clinical outcomes were improved with higher TMS, from × 106 to 12 × 106 [38]. Furthermore, regarding the sperm parameters, TMS was found to be an independent factor for clinical pregnancy after IUI in accordance with many authors [28, 63, 74, 77, 79–81]. However, Ozkan et al. [82] found just a minimal influence of TMS on the IUI success after TMS is a key factor for choosing IUI treatment or IVF, although a TMS threshold value of 5 × 106 to 10 × 106 has been reported as the criterion for undergoing IVF. Nevertheless, other sperm parameters could be better predictors of sperm morphology [58]. Although the predictive weakness of conventional sperm parameters for ART clinical outcomes has been demonstrated, sperm genome decay tests [83] could become a strong diagnostic tool to achieve clinical pregnancy for infertile couples undergoing homologous predictive factors for success have been found in some studies, such as duration of infertility, body mass index [15, 60, 82, 84, 85], and smoking [37], which were not regularly noted in our records and, therefore, could not be ConclusionThis study, is in concordance with our preliminary work [86] and demonstrate that there is no significant difference in clinical outcomes between different COS protocols rFSH, uFSH, or hMG and infertility types, even after taking into account the usual prognostic factors, including the female's age, the IUI attempt rank, and the sperm quality. However, unexplained infertility had a significant impact on IUI success, which revealed the need to look for more efficient ART strategies. Furthermore, since the fourth IUI attempt or with the female aged over 40 years, clinical pregnancy declined in IUI. Regarding the sperm quality, TMS with a threshold of 5 × 106 seemed a good predictor for IUI success. Indeed, over the obtained cut-off of the chosen indicators, other ART techniques might be more favourable for IVF live-birth infertile patients with male factor, sperm concentration was a determinant to achieve pregnancy, which necessitated some additional tests, such as sperm genome decay tests, before undergoing IUI and reviewing the couple's etiological factors for antioxidant prescriptions. Finally, every decision must be individualized to each couple's profile taking into account factors involved in the success of authors acknowledge the help of the embryology team of the IVF Centre of Amiens Hospital and the andrology team of Eylau Laboratory, Paris. This work was supported by the University Hospital and School of Medicine, Amiens, and Eyalu/Unilabs, reproductive technologiesCOSControlled ovarian stimulationIUIIntrauterine inseminationPCOSPolycystic ovaries syndromeTMSTotal motile of InterestThe authors declare that there are no conflicts of interest regarding the publication of this Boivin J., Bunting L., Collins J. A., Nygren K. G. International estimates of infertility prevalence and treatment-seeking potential need and demand for infertility medical care. Human Reproduction. 2007;2261506–1512. doi [PubMed] [CrossRef] [Google Scholar]2. Bushnik T., Cook J. L., Yuzpe A. A., Tough S., Collins J. Estimating the prevalence of infertility in Canada. Human Reproduction. 2012;273738–746. doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]3. Thoma M. E., McLain A. C., Louis J. F., et al. Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertility and Sterility. 2013;9951324– doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]4. Slama R., Hansen O. K. H., Ducot B., et al. Estimation of the frequency of involuntary infertility on a nation-wide basis. Human Reproduction. 2012;2751489–1498. doi [PubMed] [CrossRef] [Google Scholar]5. The ESHRE Capri Workshop Group. Intrauterine insemination. Human Reproduction Update. 2009;153265–277. doi [PubMed] [CrossRef] [Google Scholar]6. Oehninger S. Place of intracytoplasmic sperm injection in management of male infertility. The Lancet. 2001;35792742068–2069. doi [PubMed] [CrossRef] [Google Scholar]7. Abdelkader A. M., Yeh J. The potential use of intrauterine insemination as a basic option for infertility a review for technology-limited medical settings. Obstetrics and Gynecology International. 2009;200911. doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]8. Katzorke T., Kolodziej F. B. Significance of insemination in the era of IVF and ICSI. Der Urologe—Ausgabe A. 2010;497842–846. doi [PubMed] [CrossRef] [Google Scholar]9. Monraisin O., Chansel-Debordeaux L., Chiron A., et al. Evaluation of intrauterine insemination practices a 1-year prospective study in seven French assisted reproduction technology centers. Fertility and Sterility. 2016;10561589–1593. doi [PubMed] [CrossRef] [Google Scholar]10. Campana A., Sakkas D., Stalberg A., et al. Intrauterine insemination evaluation of the results according to the woman's age, sperm quality, total sperm count per insemination and life table analysis. Human Reproduction. 1996;114732–736. doi [PubMed] [CrossRef] [Google Scholar]11. Khalil M. R., Rasmussen P. E., Erb K., Laursen S. B., Rex S., Westergaard L. G. Homologous intrauterine insemination. An evaluation of prognostic factors based on a review of 2473 cycles. Acta Obstetricia et Gynecologica Scandinavica. 2001;80174–81. doi [PubMed] [CrossRef] [Google Scholar]12. Kamath M. S., Bhave P. T. K., Aleyamma T. K., et al. Predictive factors for pregnancy after intrauterine insemination a prospective study of factors affecting outcome. Journal of Human Reproductive Sciences. 2010;33129–134. doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]13. Tijani H. A., Bhattacharya S. The role of intrauterine insemination in male infertility. Human Fertility. 2010;134226–232. doi [PubMed] [CrossRef] [Google Scholar]14. Souter I., Baltagi L. M., Kuleta D., Meeker J. D., Petrozza J. C. Women, weight, and fertility the effect of body mass index on the outcome of superovulation/intrauterine insemination cycles. Fertility and Sterility. 2011;9531042–1047. doi [PubMed] [CrossRef] [Google Scholar]15. Soria M., Pradillo G., García J., et al. Pregnancy predictors after intrauterine insemination analysis of 3012 cycles in 1201 couples. Journal of Reproduction and Infertility. 2012;133158–166. [PMC free article] [PubMed] [Google Scholar]16. Dilbaz B., Özkaya E., Çinar M. Predictors of total gonadotropin dose required for follicular growth in controlled ovarian stimulation with intrauterin insemination cycles in patients with unexplained infertility or male subfertility. Gynecology, Obstetrics and Reproductive Medicine. 2001;17120016 [Google Scholar]17. Goverde A. J., McDonnell J., Vermeiden J. P. W., Schats R., Rutten F. F. H., Schoemaker J. Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility a randomised trial and cost-effectiveness analysis. The Lancet. 2000;355919713–18. doi [PubMed] [CrossRef] [Google Scholar]18. Kim D., Child T., Farquhar C. Intrauterine insemination A UK survey on the adherence to NICE clinical guidelines by fertility clinics. BMJ Open. 2015;55 doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]19. Prado-Perez J., Navarro-Maritnez C., Lopez-Rivadeneira E., Sanon-Julien Flores E. The impact of endometriosis on the rate of pregnancy of patients submitted to intrauterine insemination. Fertility and Sterility. 2002;77supplement 1p. S51. doi [CrossRef] [Google Scholar]20. Dmowski W. P., Pry M., Ding J., Rana N. Cycle-specific and cumulative fecundity in patients with endometriosis who are undergoing controlled ovarian hyperstimulation-intrauterine insemination or in vitro fertilization-embryo transfer. Fertility and Sterility. 2002;784750–756. doi [PubMed] [CrossRef] [Google Scholar]21. Härkki P., Tiitinen A., Ylikorkala O. Endometriosis and assisted reproduction techniques. Annals of the New York Academy of Sciences. 2010;1205207–213. doi [PubMed] [CrossRef] [Google Scholar]22. Matorras R., Recio V., Corcóstegui B., Rodríguez-Escudero F. J. Recombinant human FSH versus highly purified urinary FSH a randomized study in intrauterine insemination with husband's spermatozoa. Human Reproduction. 2000;1561231–1234. doi [PubMed] [CrossRef] [Google Scholar]23. Gerli S., Bini V., Renzo G. C. D. Cost-effectiveness of recombinant follicle-stimulating hormone FSH versus human FSH in intrauterine insemination cycles a statistical model-derived analysis. Gynecological Endocrinology. 2008;24118–23. doi [PubMed] [CrossRef] [Google Scholar]24. Ragni G., Alagna F., Brigante C., et al. GnRH antagonists and mild ovarian stimulation for intrauterine insemination A randomized study comparing different gonadotrophin dosages. Human Reproduction. 2004;19154–58. doi [PubMed] [CrossRef] [Google Scholar]25. Demirol A., Gurgan T. Comparison of different gonadotrophin preparations in intrauterine insemination cycles for the treatment of unexplained infertility a prospective, randomized study. Human Reproduction. 2007;22197–100. doi [PubMed] [CrossRef] [Google Scholar]26. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. Geneva, Switzerland World Health Organization; 2010. [Google Scholar]27. Ombelet W., Puttemans P., Bosmans E. Intrauterine insemination a first-step procedure in the algorithm of male subfertility treatment. Human Reproduction. 1995;10supplement 190–102. doi [PubMed] [CrossRef] [Google Scholar]28. Ibérico G., Vioque J., Ariza N., et al. Analysis of factors influencing pregnancy rates in homologous intrauterine insemination. Fertility and Sterility. 2004;8151308–1313. doi [PubMed] [CrossRef] [Google Scholar]29. Steures P., van der Steeg J. W., Hompes P. G., et al. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis a randomised clinical trial. The Lancet. 2006;3689531216–221. doi [PubMed] [CrossRef] [Google Scholar]30. Merviel P., Heraud M. H., Grenier N., Lourdel E., Sanguinet P., Copin H. Predictive factors for pregnancy after intrauterine insemination IUI an analysis of 1038 cycles and a review of the literature. Fertility and Sterility. 2010;93179–88. doi [PubMed] [CrossRef] [Google Scholar]31. Moro F., Scarinci E., Palla C., et al. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years a RCT. Human Reproduction. 2015;301179–185. doi [PubMed] [CrossRef] [Google Scholar]32. Dickey R. P., Olar T. T., Taylor S. N., Curole D. N., Rye P. H. Sequential clomiphene citrate and human menopausal gonadotrophin for ovulation induction comparison to clomiphene citrate alone and human menopausal gonadotrophin alone. Human Reproduction. 1993;8156–59. doi [PubMed] [CrossRef] [Google Scholar]33. Manganiello P. D., Stern J. E., Stukel T. A., Crow H., Brinck-Johnsen T., Weiss J. E. A comparison of clomiphene citrate and human menopausal gonadotropin for use in conjunction with intrauterine insemination. Fertility and Sterility. 1997;683405–412. doi [PubMed] [CrossRef] [Google Scholar]34. Guzick D. S., Sullivan M. W., Adamson G. D., et al. Efficacy of treatment for unexplained infertility. Fertility and Sterility. 1998;702207–213. doi [PubMed] [CrossRef] [Google Scholar]35. Hughes E. G. timulated intra‐uterine insemination is not a natural choice for the treatment of unexplained subfertility 'Effective treatment' or 'not a natural choice'? Human Reproduction. 2003;185912–914. doi [PubMed] [CrossRef] [Google Scholar]36. Erdem M., Abay S., Erdem A., et al. Recombinant FSH increases live birth rates as compared to clomiphene citrate in intrauterine insemination cycles in couples with subfertility a prospective randomized study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015;18933–37. doi [PubMed] [CrossRef] [Google Scholar]37. Hassan M. A. M., Killick S. R. Negative lifestyle is associated with a significant reduction in fecundity. Fertility and Sterility. 2004;812384–392. doi [PubMed] [CrossRef] [Google Scholar]38. Dinelli L., Courbière B., Achard V., et al. Prognosis factors of pregnancy after intrauterine insemination with the husband's sperm conclusions of an analysis of 2,019 cycles. Fertility and Sterility. 2014;1014994–1000. doi [PubMed] [CrossRef] [Google Scholar]39. Cohlen B. J., Vandekerckhove P., te Velde E. R., Habbema J. D. Timed intercourse versus intra‐uterine insemination with or without ovarian hyperstimulation for subfertility in men. The Cochrane Library. 2007 [PubMed] [Google Scholar]40. Bry-Gauillard H., Coulondre S., Cédrin-Durnerin I., Hugues J. N. Advantages and risks of ovarian stimulation before intra-uterine inseminations. Gynécologie Obstétrique & Fertilité 2000;2811820–831. doi [PubMed] [CrossRef] [Google Scholar]41. Casadei L., Zamaro V., Calcagni M., Ticconi C., Dorrucci M., Piccione E. Homologous intrauterine insemination in controlled ovarian hyperstimulation cycles a comparison among three different regimens. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2006;1292155–161. doi [PubMed] [CrossRef] [Google Scholar]42. Cantineau A. E., Cohlen B. J., Heineman M. J. Ovarian stimulation protocols anti‐oestrogens, gonadotrophins with and without GnRH agonists/antagonists for intrauterine insemination IUI in women with subfertility. The Cochrane Library. 2007 [PubMed] [Google Scholar]43. Dankert T., Kremer J. A. M., Cohlen B. J., et al. A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility. Human Reproduction. 2007;223792–797. doi [PubMed] [CrossRef] [Google Scholar]44. Gerli S., Casini M. L., Unfer V., Costabile L., Bini V., Di Renzo G. C. Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles A prospective, randomized analysis of cost effectiveness. Fertility and Sterility. 2004;823573–578. doi [PubMed] [CrossRef] [Google Scholar]45. Kocak M., Dilbaz B., Demir B., et al. Lyophilised hMG versus rFSH in women with unexplained infertility undergoing a controlled ovarian stimulation with intrauterine insemination a prospective, randomised study. Gynecological Endocrinology. 2010;266429–434. doi [PubMed] [CrossRef] [Google Scholar]46. Sagnella F., Moro F., Lanzone A., et al. A prospective randomized noninferiority study comparing recombinant FSH and highly purified menotropin in intrauterine insemination cycles in couples with unexplained infertility and/or mild-moderate male factor. Fertility and Sterility. 2011;952689–694. doi [PubMed] [CrossRef] [Google Scholar]47. Matorras R., Osuna C., Exposito A., Crisol L., Pijoan J. I. Recombinant FSH versus highly purified FSH in intrauterine insemination systematic review and metaanalysis. Fertility and Sterility. 2011;9561937–e3. doi [PubMed] [CrossRef] [Google Scholar]48. Balasch J., Fábregues F., Peñarrubia J., et al. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO group II anovulatory infertile patients. Journal of Assisted Reproduction and Genetics. 1998;159552–559. doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]49. Balasch J., Miró F., Burzaco I., et al. Endocrinology The role of luteinizing hormone in human follicle development and oocyte fertility Evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Human Reproduction. 1995;1071678–1683. doi [PubMed] [CrossRef] [Google Scholar]50. Vlahos N. F., Coker L., Lawler C., Zhao Y., Bankowski B., Wallach E. E. Women with ovulatory dysfunction undergoing ovarian stimulation with clomiphene citrate for intrauterine insemination may benefit from administration of human chorionic gonadotropin. Fertility and Sterility. 2005;8351510–1516. doi [PubMed] [CrossRef] [Google Scholar]51. De la Fuente A. Evaluation of the effectiveness, safety and cost-effectiveness of highly purified human menopausal gonadotropin. Study of use Menopur Ⓡ in Intrauterine Artificial Insemination IAC/IAD Fertility Review. 2007;24363–367. [Google Scholar]52. Filicori M., Cognigni G. E., Pocognoli P., et al. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertility and Sterility. 2003;802390–397. doi [PubMed] [CrossRef] [Google Scholar]53. Gomez R., Schorsch M., Steetskamp J., et al. The effect of ovarian stimulation on the outcome of intrauterine insemination. Archives of Gynecology and Obstetrics. 2014;2891181–185. doi [PubMed] [CrossRef] [Google Scholar]54. Isaza V., Requena A., García-Velasco J. A., Remohí J., Pellicer A., Simón C. Recombinant versus urinary follicle-stimulating hormone in couples undergoing intrauterine insemination a randomized study. Obstetrics, Gynaecology and Reproductive Medicine. 2003;482112–118. [PubMed] [Google Scholar]55. Gallot-Lavallée P., Ecochard R., Mathieu C., et al. Clomiphene citrate or hMg which ovarian stimulation to chose before intra-uterine inseminations? A meta-analysis. Contraception, Fertilite, Sexualite. 1995;23115–121. [PubMed] [Google Scholar]56. Dickey R. R., Ramasamy R. Role of male factor testing in recurrent pregnancy loss or in vitro fertilization failure. Reproductive System & Sexual Disorders. 2015;0403 doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]57. Hansen K. R., He A. L. W., Styer A. K., et al. Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation–intrauterine insemination. Fertility and Sterility. 2016;10561575– doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]58. Erdem M., Erdem A., Mutlu M. F., et al. The impact of sperm morphology on the outcome of intrauterine insemination cycles with gonadotropins in unexplained and male subfertility. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016;197120–124. doi [PubMed] [CrossRef] [Google Scholar]59. NICE. Nice guideline Fertility for people with fertility problems. NICE clinical guideline 156 February, Nuojua-Huttunen S., Tomas C., Bloigu R., Tuomivaara L., Martikainen H. Intrauterine insemination treatment in subfertility an analysis of factors affecting outcome. Human Reproduction. 1999;143698–703. doi [PubMed] [CrossRef] [Google Scholar]61. Toma S. K., Stovall D. W., Hammond M. G. The effect of laparoscopic ablation or danocrine on pregnancy rates in patients with stage I or II endometriosis undergoing donor insemination. Obstetrics & Gynecology. 1992;802253–256. [PubMed] [Google Scholar]62. Blasco V., Prados N., Carranza F., González-Ravina C., Pellicer A., Fernández-Sánchez M. Influence of follicle rupture and uterine contractions on intrauterine insemination outcome a new predictive model. Fertility and Sterility. 2014;10241034–1040. doi [PubMed] [CrossRef] [Google Scholar]63. Van Voorhis B. J., Barnett M., Sparks A. E. T., Syrop C. H., Rosenthal G., Dawson J. Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization. Fertility and Sterility. 2001;754661–668. doi [PubMed] [CrossRef] [Google Scholar]64. Mathieu C., Ecochard R., Bied V., Lornage J., Czyba J. C. Andrology cumulative conception rate following intrauterine artificial insemination with husband's spermatozoa influence of husband's age. Human Reproduction. 1995;1051090–1097. doi [PubMed] [CrossRef] [Google Scholar]65. Brzechffa P. R., Daneshmand S., Buyalos R. P. Sequential clomiphene citrate and human menopausal gonadotrophin with intrauterine insemination the effect of patient age on clinical outcome. Human Reproduction. 1998;1382110–2114. doi [PubMed] [CrossRef] [Google Scholar]66. Bakas P., Boutas I., Creatsa M., et al. Can anti-Mullerian hormone AMH predict the outcome of intrauterine insemination with controlled ovarian stimulation? Gynecological Endocrinology. 2015;3110765–768. doi [PubMed] [CrossRef] [Google Scholar]67. Hendin B. N., Falcone T., Hallak J., et al. The effect of patient and semen characteristics on live birth rates following intrauterine insemination a retrospective study. Journal of Assisted Reproduction and Genetics. 2000;175245–252. doi [PMC free article] [PubMed] [CrossRef] [Google Scholar]68. Aydin Y., Hassa H., Oge T., Tokgoz V. Y. Factors predictive of clinical pregnancy in the first intrauterine insemination cycle of 306 couples with favourable female patient characteristics. Human Fertility. 2013;164286–290. doi [PubMed] [CrossRef] [Google Scholar]69. Plosker S. M., Jacobson W., Amato P. Infertility Predicting and optimizing success in an intra-uterine insemination programme. Human Reproduction. 1994;9112014–2021. doi [PubMed] [CrossRef] [Google Scholar]70. Oehninger S., Franken D., Kruger T. Approaching the next millennium How should we manage andrology diagnosis in the intracytoplasmic sperm injection era? Fertility and Sterility. 1997;673434–436. doi [PubMed] [CrossRef] [Google Scholar]71. Dorjpurev U., Kuwahara A., Yano Y., et al. Effect of semen characteristics on pregnancy rate following intrauterine insemination. Journal of Medical Investigation. 2011;581-2127–133. doi [PubMed] [CrossRef] [Google Scholar]72. Duran H. E., Morshedi M., Kruger T., Oehninger S. Intrauterine insemination a systematic review on determinants of success. Human Reproduction Update. 2002;84373–384. doi [PubMed] [CrossRef] [Google Scholar]73. Belaisch-Allart J., Mayenga J. M., Plachot M. Intra-uterine insemination. Contraception, fertilité, sexualité 1992 1999;279614–619. [PubMed] [Google Scholar]74. Sakhel K., Abozaid T., Schwark S., Ashraf M., Abuzeid M. Semen parameters as determinants of success in 1662 cycles of intrauterine insemination after controlled ovarian hyperstimulation. Fertility and Sterility. 2005;84S248–S249. doi [CrossRef] [Google Scholar]75. Stone B. A., Vargyas J. M., Ringlet G. E., et al. Determinants of the outcome of intrauterine insemination analysis of outcomes of 9963 consecutive cycles. American Journal of Obstetrics & Gynecology. 1999;1806 I1522–1534. doi [PubMed] [CrossRef] [Google Scholar]76. Strandell A., Bergh C., Söderlund B., Lundin K., Nilsson L. Fallopian tube sperm perfusion the impact of sperm count and morphology on pregnancy rates. Acta Obstetricia et Gynecologica Scandinavica. 2003;82111023–1029. doi [PubMed] [CrossRef] [Google Scholar]77. Huang Lee Lai et al. The impact of the total motile sperm count on the success of intrauterine insemination with husband's spermatozoa. Journal of Assisted Reproduction and Genetics. 1996;13156–63. doi [PubMed] [CrossRef] [Google Scholar]78. Dickey R. P., Pyrzak R., Lu P. Y., Taylor S. N., Rye P. H. Comparison of the sperm quality necessary for successful intrauterine insemination with World Health Organization threshold values for normal sperm. Fertility and Sterility. 1999;714684–689. doi [PubMed] [CrossRef] [Google Scholar]79. Miller D. C., Hollenbeck B. K., Smith G. D., et al. Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination. Urology. 2002;603497–501. doi [PubMed] [CrossRef] [Google Scholar]80. Yousefi B., Azargon A. Predictive factors of intrauterine insemination success of women with infertility over 10 years. Journal of the Pakistan Medical Association. 2011;612165–168. [PubMed] [Google Scholar]81. Yavuz A., Demirci O., Sözen H., Uludoğan M. Predictive factors influencing pregnancy rates after intrauterine insemination. Iranian Journal of Reproductive Medicine. 2013;113227–234. [PMC free article] [PubMed] [Google Scholar]82. Ozkan Z. S., Ilhan R., Ekinci M., Timurkan H., Sapmaz E. Impact of estradiol monitoring on the prediction of intrauterine insemination outcome. Journal of Taibah University Medical Sciences. 2014;9136–40. doi [CrossRef] [Google Scholar]83. Kaarouch I., Bouamoud N., Louanjli N., et al. Impact of sperm genome decay on Day-3 embryo chromosomal abnormalities from advanced-maternal-age patients. Molecular Reproduction and Development. 2015;8210809–819. doi [PubMed] [CrossRef] [Google Scholar]84. Snick H. K. A., Snick T. S., Evers J. L. H., Collins J. A. The spontaneous pregnancy prognosis in untreated subfertile couples the Walcheren primary care study. Human Reproduction. 1997;1271582–1588. doi [PubMed] [CrossRef] [Google Scholar]85. Collins J. Current best evidence for the advanced treatment of unexplained subfertility. Human Reproduction. 2003;185907–912. doi [PubMed] [CrossRef] [Google Scholar]86. Cabry-Coubert R., Scheffler F., Belhadri-Mansouri N., et al. Effect of Gonadotropin types and indications on homologous intrauterine insemination success A Study from 1251 Cycles and a review of the literature, Rbm Online, 2016. [PMC free article] [PubMed]Articles from BioMed Research International are provided here courtesy of Hindawi Limited

./ 17:54:59 29.0 MiB containerd.io-.1.el8.x86_64.rpm 2020-12-01 19:46:33 29.0 MiB containerd.io-1.4.10-3.1

球员名单球队简介名称：广东主教练：杜锋助理教练：伊戈尔领队：马永忠创建时间：1993 最好成绩：2003-04，04-05，05-06，07-08，08-09，09-10，10-11赛季总冠军给球队打分平均得分参与人数 30326 球队微集体一键关注 CBA联赛21-22 场均总计号码球员场次出场时间 2分球 3分球罚球进攻篮板防守篮板助攻抢断灌篮盖帽失误犯规得分 9 易建联 37 53% 39% 81% 11 周鹏 38 50% 44% 67% 12 苏伟 36 57% 0% 61% 20 任骏飞 34 56% 31% 74% 10 赵睿 26 54% 34% 75% 5 王薪凯 29 48% 33% 94% 22 曾繁日 41 55% 0% 56% 3 胡明轩 45 52% 34% 80% 13 威姆斯 27 53% 40% 82% 2 徐杰 43 53% 39% 90% 18 杜润旺 33 75% 45% 67% 32 里卡多-雷多 18 49% 37% 85% 0 刘权标 9 61% 33% 67% 25 张皓嘉 14 60% 41% 92% 30 汤杰 12 29% 25% 90% 17 赵锦洋 18 65% 42% 60% 21 张昊 12 53% 25% 58% 1 马力克 7 33% 0% 22% 27 张明池 12 58% 50% 75% 19 徐昕 6 58% 0% 71% CBA联赛近期赛程赛果时间对手 2分球 3分球罚球进攻篮板防守篮板助攻抢断灌篮盖帽失误犯规得分 2021-10-16 主场 10683 深圳 30-61 49% 11-29 38% 13-18 72% 14 31 31 10 0 5 16 25 106 2021-10-18 客场 10390 青岛 20-47 43% 17-33 52% 12-14 86% 13 31 29 6 0 5 16 19 103 2021-10-21 主场 11094 浙江 30-57 53% 11-28 39% 17-24 71% 16 30 29 13 1 9 13 31 110 2021-10-24 客场 11297 上海 33-58 57% 9-21 43% 19-27 70% 10 36 31 8 0 4 16 24 112 2021-10-26 主场 111108 四川 29-60 48% 12-32 38% 17-24 71% 19 36 18 5 1 5 8 13 111 2021-10-28 客场 10690 深圳 28-52 54% 8-24 33% 26-31 84% 12 32 23 5 1 6 17 22 106 2021-10-30 客场 101124 浙江 29-58 50% 5-26 19% 28-38 74% 12 27 11 8 0 9 15 31 101 2021-11-01 主场 9891 福建 36-57 63% 3-15 20% 17-26 65% 14 30 30 5 0 4 17 20 98 2021-11-04 客场 9784 江苏 26-40 65% 8-19 42% 21-32 66% 8 35 30 9 2 8 21 18 97 2021-11-06 主场 6791 北京 20-46 43% 4-20 20% 15-22 68% 6 28 15 8 1 2 13 16 67 2021-11-09 客场 11098 天津 28-46 61% 10-22 45% 24-31 77% 7 43 30 6 2 8 31 23 110 2021-11-12 主场 10873 江苏 23-48 48% 9-22 41% 35-46 76% 17 27 34 16 1 3 22 23 108 2021-11-14 客场 9280 北京 26-39 67% 8-20 40% 16-22 73% 2 20 24 14 3 3 19 30 92 2021-12-26 客场 8698 广厦 20-41 49% 9-40 23% 19-23 83% 12 21 25 11 0 1 20 32 86 2021-12-28 主场 99125 山西 20-45 44% 11-23 48% 26-30 87% 5 29 22 3 0 5 23 18 99 2021-12-30 客场 11699 吉林 32-48 67% 13-26 50% 13-15 87% 10 32 33 4 1 5 17 18 116 2022-01-01 主场 95115 辽宁 22-43 51% 11-32 34% 18-21 86% 12 25 29 6 3 7 16 19 95 2022-01-03 客场 10186 同曦 32-55 58% 6-11 55% 19-21 90% 9 31 28 8 7 8 24 21 101 2022-01-06 客场 11196 山西 32-56 57% 8-21 38% 23-31 74% 12 37 33 7 2 4 15 22 111 2022-01-08 主场 9995 吉林 31-52 60% 3-9 33% 28-33 85% 13 35 24 6 5 6 25 22 99 2022-01-10 主场 10187 同曦 28-54 52% 4-11 36% 33-42 79% 7 34 26 5 1 5 20 25 101 2022-01-13 客场 90102 辽宁 20-44 45% 10-28 36% 20-24 83% 9 34 26 6 4 6 23 29 90 2022-01-15 主场 94114 广厦 18-39 46% 15-30 50% 13-20 65% 7 22 19 4 3 5 14 12 94 2022-01-18 客场 108104 福建 29-50 58% 11-26 42% 17-23 74% 14 30 34 9 2 1 16 20 108 2022-01-21 主场 11891 天津 32-42 76% 14-38 37% 12-15 80% 11 34 34 7 3 3 13 24 118 2022-01-23 主场 9891 青岛 14-34 41% 13-35 37% 31-37 84% 9 31 23 9 1 3 21 20 98 2022-01-26 客场 11076 四川 28-43 65% 11-32 34% 21-29 72% 6 42 27 8 1 3 10 14 110 2022-01-28 主场 101108 上海 30-58 52% 9-26 35% 14-21 67% 10 24 25 8 2 5 13 13 101 2022-03-01 主场 127101 山东 36-57 63% 11-25 44% 22-25 88% 8 36 34 11 4 4 14 27 127 2022-03-03 客场 107109 新疆 35-64 55% 7-19 37% 16-23 70% 13 28 29 7 4 3 21 31 107 2022-03-05 主场 9889 广州 22-46 48% 12-31 39% 18-22 82% 10 33 23 6 1 1 15 21 98 2022-03-09 客场 93106 北控 29-55 53% 5-30 17% 20-28 71% 8 32 17 8 1 5 21 26 93 2022-03-11 主场 11188 宁波 33-60 55% 7-19 37% 24-33 73% 14 33 25 9 4 2 18 23 111 2022-03-13 客场 101120 广州 25-51 49% 7-28 25% 30-36 83% 12 27 24 6 1 2 12 26 101 2022-03-15 主场 10980 北控 28-55 51% 11-27 41% 20-27 74% 20 37 29 10 1 2 18 25 109 2022-03-18 客场 10680 宁波 25-43 58% 11-30 37% 23-34 68% 4 35 30 10 2 1 11 18 106 2022-03-20 主场 11899 新疆 36-63 57% 12-26 46% 10-13 77% 11 25 30 15 2 2 16 20 118 2022-03-22 客场 110111 山东 23-52 44% 16-35 46% 16-27 59% 11 34 32 9 0 1 20 27 110 2022-04-01 主场 124101 天津 27-43 63% 17-30 57% 19-25 76% 7 33 31 9 2 0 19 20 124 2022-04-03 客场 122104 天津 42-57 74% 7-25 28% 17-19 89% 8 36 30 6 5 2 14 22 122 2022-04-07 客场 9998 浙江 21-54 39% 13-26 50% 18-21 86% 14 26 21 10 2 5 12 24 99 2022-04-09 主场 9782 浙江 23-56 41% 7-19 37% 30-35 86% 15 33 17 6 4 6 16 24 97 2022-04-12 客场 7992 辽宁 13-34 38% 11-30 37% 20-33 61% 9 30 19 5 0 4 21 24 79 2022-04-14 客场 8396 辽宁 18-41 44% 11-33 33% 14-19 74% 4 24 16 11 0 4 9 22 83 2022-04-16 主场 116117 辽宁 24-50 48% 15-38 39% 23-27 85% 13 29 29 12 1 3 17 28 116

Allthese matching pfps are square in size so you can use them on any platform.Matching pfp, matching profile pictures, nanami, cute icons.Matching pfp couples dwo girls. Cartoons, gamers, couples, friends, and funny pfps.Cute Matching Pfp For Couples Girls - Pin By H On Matching Pfps Anime Anime Icons Avatar Couple. There are times that you. Mar 1, 2021 - Explore

How to calculate 33 percent-off $ How to figure out percentages off a price. Using this calculator you will find that the amount after the discount is $ To find any discount, just use our Discount Calculator above. Using this calculator you can find the discount value and the discounted price of an item. It is helpfull to answer questions like What is 33 percent % off $ What is $ minus 33 percent % off? How to calculate 33 percent off $ How much will you pay for an item where the original price before discount is $ when discounted 33 percent %? What is the final or sale price? $ is what percent off $ Percent-off Formulas To calculate discount it is ease by using the following formulas a Amount Saved = Orig. Price x Discount % / 100 b Sale Price = Orig. Price - Amount Saved How to calculate 33 Percent-off Now, let's solve the questions stated above FAQs on Percent-off What's 33 percent-off $ Replacing the given values in formula a we have Amount Saved = Original Price x Discount in Percent / 100. So, Amount Saved = x 33 / 100 Amount Saved = / 100 Amount Saved = $ answer. In other words, a 33% discount for a item with original price of $ is equal to $ Amount Saved. Note that to find the amount saved, just multiply it by the percentage and divide by 100. What's the final price of an item of $ when discounted $ Using the formula b and replacing the given values Sale Price = Original Price - Amount Saved. So, Sale Price = - Sale Price = $58 answer. This means the cost of the item to you is $58. You will pay $58 for a item with original price of $ when discounted 33%. In this example, if you buy an item at $ with 33% discount, you will pay - = 58 dollars. is what percent off dollars? Using the formula b and replacing given values Amount Saved = Original Price x Discount in Percent /100. So, = x Discount in Percent / 100 / = Discount in Percent /100 100 x / = Discount in Percent / = Discount in Percent, or Discount in Percent = 33 answer. To find more examples, just choose one at the bottom of this page. ^{Cenuméro a été consulté 0 fois hier et 1 fois aujourd'hui. Le rythme de consultation du numéro est anormalement basse, la moyenne est habituellement de 1 consultations/jour. Une} Milan Day Matka Jodi ChartMonTueWedThuFriSatSun840119677007549195196214132434236146902960**4281536554480203112872****22675495907887356202320561625563203533913611431137936221539491295722890653950822140346506318758103060429**033969569668902515765322220951552140978518944859208866013555911438558897594552656360070776700219273771273265760103251665202893121337343549213408260813822934229808175555216542901378518535861240277158599508784961112622131042177024899837607212049399*64840020368825387248976234095477776311827775*330750976992548676187108323034546388*039951066472664045611612506053105719860842415700694769562059022016246471284562540031996188077154166381**********8216913544494722503428153975994138993824579284299709277367869885031604890731052211261866151208755751636913335651699998489266013535776667832705750507653643464377340606*7415366306629329187631024414793352598884881431689069712494978451197795 0267749515638606**1842092704176255827353******************5485178226**37071867190347445889245403303219504217985504990564749744997852837834188844431941403803677719878168447209940072002717388052603779595547397573867166023162907078911590****971287886815**6666538219383147852292171792048030446299038706497887316618440320652958800104154590323691916542572418608198923914899420622361454395620067146608571928268817********************2347709845553450002275070058792186480195180141701903900695312423681924660227862244743016568755478398682894404656016695792565536944339269**713821029473235959538770377913672828649157564867902608186235574096484556124801856415782329435117642521542175606730272452****217125152107335397186584364948138589291767528007885592332208197456590619874472145778269673000989626613618189321543995918004216580196695432941372518928862971358140288823160543460142302735521636611236039076780903074368463303711997161641994220323520064520295191804184461383122538**594123295317**09355175997015010992417455308639492171****721789202519**3327481098224690920686323136741011055757072788265864151341577277807655962173348384******************910909877035994251050311424919407105142706438795925826124177807756547133583020772007395239971279950901805226261193880298280914850903360853534963**2648512359**233903287695845852****346358199444**265081348360**411552999286**834387893183**740062381123**44874410**28**162646872613**765214308644**602333519966**177265335420**735140650165**274522289348**247920275172**1683**908955**980459338693**206619011498**994542676761**863460407978**026634234200**231804463263**488769526409**363473133417**785541613849**454554852215**492467144815**661429059195**004129782535****81 NationalWeather Service Southern Region Headquarters Fort Worth, Texas Disclaimer Color Harmonies Scheme Complementary The complementary color of 56,33,86 is 63,86,33. When combined, they cancel each other out this means that they produce a grayscale color. When placed next to each other, they create the strongest contrast. Triad A triadic color scheme use three colors that are evenly spaced around the color wheel. Triadic color harmonies tend to be quite vibrant, even if you use pale or unsaturated versions of your hues. To use a triadic harmony successfully, the colors should be carefully balanced - let one color dominate 56,33,86 and use the two others for accent 86,56,33, 33,86,56. Square The square color scheme has four colors spaced evenly around the color circle. This creates a balance between warm 86,33,37, 63,86,33 and cool 56,33,86, 33,86,82 colors in your design. The square color scheme works best if you let one color be dominant. Adjacent / Analogous / Analogic Dominance Harmony Analogous color schemes use colors that are next to each other on the color wheel. They usually match well and create serene and comfortable designs. The nearest colors, with enough contrast, of 56,33,86 are 82,33,86 and 33,37,86. Choose one color to dominate and a second to support. The third color is used along with black, white or gray as an accent. Split ComplementaryCompound Harmony The split-complementary color scheme is a variation of the complementary color scheme. In addition to the base color 56,33,86, it uses the two colors adjacent to its complement 86,82,33 and 37,86,33. This color scheme has the same strong visual contrast as the complementary color scheme, but has less tension. The split-complimentary color scheme is often a good choice for beginners, because it is difficult to mess up. Rectangle Tetradic The rectangle or tetradic color scheme uses four colors arranged into two complementary pairs 56,33,86 and his complementary 63,86,33 with 86,33,63 33,86,56 or 86,56,33 33,63,86. This rich color scheme offers plenty of possibilities for variation. The tetradic color scheme works best if you let one color be dominant. You should also pay attention to the balance between warm and cool colors in your design. Tints, Shades, and Tones Tints Adding white to the color same hue and saturation of 56,33,86, but brighter. Shades Adding black to the color same hue and saturation of 56,33,86, but darker. Tones Adding gray to the color same hue and luminosity of 56,33,86, but less saturation. SIMILAR COLORS Colors with similar hue of 56,33,86. Demantes 14/9/2020 17:51. butée de débattement de pont arrière. pinpon87. 13/9/2020 20:59. butée de débattement de pont arrière. freducoin. 13/9/2020 11:55. butée de débattement de pont arrière.

appears to be located in Milwaukee, United states and allocated to Charter Communications Inc. Autonomous System Number ASN code for is AS10796. IP Address local time zone is America/Chicago -0500. PTR record is set to IP location database updated on Jun 08, 2019 525 AM - Refresh Now IP Address Reverse DNS / Hostname / PTR City Milwaukee Region Wisconsin Country United states US Organization / ISP Charter Communications Inc Latitude / Longitude Zipcode / Postcode 53210 TimeZone America/Chicago -0500 Calling Code +1 Currency USD Languages en-US, es-US, haw, fr ASN AS10796 IS BLACKLISTED? Take the blacklist check! Is this IP a Proxy or VPN? IP Proxy Checker Who owns this IP? IP WHOIS Check HIDE IP? Use a VPN or Proxy! Milwaukee, Charter Communications Inc on Maps is located on Latitude and Longtitude You can find coordinates on Google maps below User Comments About

2901-2022 qtRT-2021, 107 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 07-03-2022 57 58 59 60 61 62 63 appears to be located in Sydney, Australia and allocated to APPLE-ENGINEERING. Autonomous System Number ASN code for is AS714. IP Address local time zone is Australia/Sydney +1100. PTR record is set to IP location database updated on Oct 07, 2020 620 PM - Refresh Now IP Address Reverse DNS / Hostname / PTR City Sydney Region New south wales Country Australia AU Organization / ISP APPLE-ENGINEERING Latitude / Longitude Zipcode / Postcode 2055 TimeZone Australia/Sydney +1100 Calling Code +61 Currency AUD Languages en-AU ASN AS714 IS BLACKLISTED? Take the blacklist check! Is this IP a Proxy or VPN? IP Proxy Checker Who owns this IP? IP WHOIS Check HIDE IP? Use a VPN or Proxy! Sydney, APPLE-ENGINEERING on Maps is located on Latitude and Longtitude You can find coordinates on Google maps below User Comments About B3wWGU.

xmc5fbxsa9.pages.dev/76

xmc5fbxsa9.pages.dev/200

xmc5fbxsa9.pages.dev/364

xmc5fbxsa9.pages.dev/863

xmc5fbxsa9.pages.dev/127

xmc5fbxsa9.pages.dev/971

xmc5fbxsa9.pages.dev/824

xmc5fbxsa9.pages.dev/935

xmc5fbxsa9.pages.dev/702

xmc5fbxsa9.pages.dev/744

xmc5fbxsa9.pages.dev/990

xmc5fbxsa9.pages.dev/474

xmc5fbxsa9.pages.dev/103

xmc5fbxsa9.pages.dev/160

xmc5fbxsa9.pages.dev/10